SECURITIES AND EXCHANGE COMMISSION
WASHINGTON D.C. 20549
FORM S-8
REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933
HUBEI PHARMACEUTICAL GROUP LTD.
(Exact name of registrant as specified in its charter)
Nevada | 000-25553 | 88-0419476 |
(State of Incorporation) | (Commission File Number) | (IRS Employer Identification No.) |
410 Park Avenue, 15th Floor, New York, NY 10022
(Address of principal executive offices)
(604) 881-2899
(Issuer's telephone number, including area code)
Pan Asia Communications Corp.
(Former name, former address and former fiscal year, if changed since last report)
CONSULTING AGREEMENTS
(Full title of plan)
CALCULATION OF REGISTRATION FEE
Title of Securities to be Registered | Amount to be registered | Proposed Maximum Offering Price Per Share | Proposed Maximum Aggregate Offering Price | Amount of Registration Fee |
Common | 2,000,000 | $0.25 | $500,000 | $46.00 |
Total | 2,000,000 | $0.25 | $500,000 | $46.00 |
(1) Estimated solely for the purpose of calculating the registration fee pursuant to Rule 457 under the Securities Act of 1933
PART I. INFORMATION REQUIRED IN SECTION 10(a) PROSPECTUS
Item 1. Plan Information
This Prospectus is part of a Registration Statement which registers an aggregate 2,000,000 shares of common stock, $.001 par value, of Hubei Pharmaceutical Group Ltd. (the "Company") which have been issued as set forth herein to the following named persons who are "Selling Shareholder":
Name | Number of Shares | Services Agreement |
Ding Hong | 750,000 | Consultant services rendered on matters of research and development, specifically identifying new active pharmaceutical ingredients or pharmaceutical products for acquisition. |
Wei Jian Ping | 400,000 | Consultant services rendered on matters of research and development, specifically acting as a liaison and coordinator for clinical studies and assistance in the development of marketing strategies. |
Erwin Heuchert | 350,000 | Consultant services with respect to the identification of export market opportunities throughout Europe and assistance in building a distribution infrastructure. |
Xiang Qian | 500,000 | Consultant services rendered on matters of research and development, specifically locating distribution partners and designing competitive product packaging.. |
Total | 2,000,000 |
On May 30, 2003, a Consulting Agreement for services was entered into with Ding Hong. On June 5, 2003, a Consulting Agreement was entered into with Erwin Heuchert. On June 12, 2003, a Consulting Agreement for services was entered into with Wei Jian Ping and, on June 13, 2003, a Consulting Agreement was entered into with Xiang Qian. The Company has been advised by the Consultants/Employees that they may sell all or a portion of their shares of common stock from time to time through securities brokers/dealers only at current market prices and that no commissions or compensation will be paid in connection therewith in excess of customary brokers commissions. Advisors and the brokers and dealers through whom sales of the shares are made may be deemed to be "underwriters" within the meaning of the Securities Act of 1933, as amended, (the "Securities Act"), and any profits realized by them on the sale of the shares may be considered to be underwriting compensation.
No other person is authorized to give any information or make any representation not contained or incorporated by reference in this Prospectus, in connection with the offer contained in this Prospectus, and, if given or made, such other information or representation must not be relied upon as having been authorized by the Company. Neither the delivery of this Prospectus nor any sale made hereunder shall, under any circumstances, create any implication that there has been no change in the affairs of the Company since the date hereof.
The shares of common stock offered hereby (the "Shares") will be sold from time to time by the individuals listed under the Selling Shareholder section of this document (the "Selling Shareholder"). The Selling Shareholder acquired the Shares pursuant to compensatory benefit plans for consulting and employment services that the Selling Shareholder provided to Hubei Pharmaceutical Group Ltd.
The sales may occur in transactions on the NASD over-the-counter market at prevailing market prices or in negotiated transactions. Hubei Pharmaceutical Group Ltd. will not receive proceeds from the sale of any of the Shares. Hubei Pharmaceutical Group Ltd. is paying for the expenses incurred in registering the Shares.
The Shares are "restricted securities" under the Securities Act of 1933 (the "1933 Act") before their sale under this Reoffer Prospectus. This Reoffer Prospectus has been prepared for the purpose of registering the Shares under the 1933 Act to allow for future sales by the Selling Shareholder to the public without restriction. To the knowledge of the Company, the Selling Shareholder have no arrangement with any brokerage firm for the sale of the Shares. The Selling Shareholder may be deemed to be an "underwriter" within the meaning of the 1933 Act. Any commissions received by a broker or dealer in connection with resales of the Shares may be deemed to be underwriting commissions or discounts under the 1933 Act.
This Reoffer Prospectus does not constitute an offer to sell or the solicitation of any offer to buy any security other than the securities covered by this Prospectus, nor does it constitute an offer or solicitation by anyone in any jurisdiction in which such offer or solicitation is not authorized, or in which the person making such offer or solicitation is not qualified to do so, or to any person to whom it is unlawful to make such offer or solicitation.
Item 2. Registrant Information and Employee Plan Annual Information.
THE COMPANY HEREBY UNDERTAKES TO FURNISH WITHOUT CHARGE TO EACH SUCH PERSON TO WHOM THIS PROSPECTUS IS DELIVERED, UPON WRITTEN OR ORAL REQUEST OF SUCH PERSON, A COPY OF ANY OR ALL OF THE DOCUMENTS DESCRIBED IN ITEM 3, PART II OF THIS REGISTRATION STATEMENT, OTHER THAN EXHIBITS TO SUCH DOCUMENTS. REQUESTS SHOULD BE ADDRESSED TO MR. REID LI, 410 PARK AVENUE, 15TH FLOOR, NEW YORK, NEW YORK 10022, (604) 881-2899.
PART II. INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
Item 3. Incorporation of Documents by Reference.
The Company has filed the following documents with the Securities and Exchange Commission within the preceding fiscal year: Quarterly Reports on Form 10QSB, for the quarters ended April 30, 2002, July 31, 2002, October 31, 2002, and April 30, 2003 and filed, respectively, on June 25, 2002, September 23, 2002, December 19, 2003 and June 25, 2003 and ; Annual Report on Form 10KSB, filed May 15, 2003 for the fiscal year ended January 31, 2003. The Company also filed reports on Form 8K on May 15, 2002, May 28, 2002, September 23, 2002, December 10, 2002, February 4, 2003, February 7, 2003 and June 25, 2003. The above referenced reports, which were previously filed with the Commission are incorporated herein by reference.
All documents filed by the Company pursuant to Section 13, or 15 (d) of the Exchange Act after the date hereof and prior to the filing of a post-effective amendment which indicates that all securities offered have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference herein and to be a part hereof from the date of filing of such documents. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Prospectus to the extent that a statement contained herein or in any other subsequently filed document which also is incorporated or deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Prospectus.
Item 4. Description of Securities
The Company is authorized to issue 100,000,000 shares of Common Stock, $0.001 par value. The Company's stock is currently traded on the OTCBB, under symbol HBEI. The presently outstanding shares of Common Stock are fully paid and non-assessable.
COMMON STOCK As of July 28, 2003, approximately 27,687,700 shares of Common Stock were outstanding.
VOTING RIGHTS. Each holder of the Common Stock shall be entitled to one vote for each share of stock standing in his name on the books of the Corporation.
DIVIDEND RIGHTS. Dividends may be declared, subject to the provisions of the laws of the State of Nevada and the Articles of Incorporation, by the Board of Directors at any regular or special meeting and may be paid in cash, property, shares of corporate stock, or any other medium. The Board of Directors may fix in advance a record date, as provided in Section 1.06 of the By-laws, prior to the dividend payment for the purposes of determining shareholders entitled to receive payment of any dividend. The Board of Directors may close the stock transfer books for such purpose for a period of not more than ten (10) days prior to the payment date of such dividend.
PREEMPTIVE RIGHTS. Except as may otherwise be provided by the Board of Directors, no holder of any shares of the stock of the Corporation, shall have any preemptive right to purchase, subscribe for, or otherwise acquire any shares of stock of the Corporation of any class now or hereafter authorized, or any securities exchangeable for or convertible into such shares, or any warrants or other instruments evidencing rights or options to subscribe for, purchase or otherwise acquire such shares.
REGISTRAR AND TRANSFER AGENT: The Company's registrar and transfer agent is Pacific Stock Transfer Company, 500 E. Warm Springs Road, Suite 240, Las Vegas, Nevada 89119.
DISSENTERS' RIGHTS: Under current Nevada law, a shareholder is afforded dissenters' rights which, if properly exercised, may require the Company to purchase his shares dissenters' rights commonly arise in extraordinary transactions such as mergers, consolidations, reorganizations, substantial asset sales, liquidating distributions, and certain amendments to the Company's certificate of incorporation.
PREFERRED STOCK There are no shares of preferred stock authorized..
Item 5. Interests of Named Experts and Counsel.
None.
Item 6. Indemnification of Directors and Officers.
Pursuant to Section 78.7502 of the Nevada Revised Statutes, the Company has the power to indemnify any person made a party to any lawsuit by reason of being a director or officer of the Company, or serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise against expenses (including attorneys' fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by him in connection with such actions suit or proceeding if he acted in good faith and in a manner he reasonably believed to be in or not opposed to the best interests of the corporation, and, with respect to any criminal action or proceeding, had no reasonable cause to believe his conduct was unlawful.
Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers or persons controlling the Company pursuant to the foregoing provisions, the Company has been informed that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities Act of 1933 and is therefore unenforceable.
Item 7. Exemption from Registration Claimed.
The Shares were issued for employment, advisory and consulting services rendered. These issuances were made in reliance on the exemption from the registration requirements of the 1933 Act, contained in Section 4(2) thereof, covering transactions not involving any public offering or not involving any "offer" or "sale".
Item 8. Exhibits.
The following documents are filed as Exhibits to this Registration Statement:
5.1 -- Opinion of Dieterich & Associates as to the validity of the shares being registered.
23.1 -- Consent of Dieterich & Associates (included in Exhibit 5.1)
23.2 -- Consent of Morgan & Company
Item 9. Undertakings.
The undersigned registrant hereby undertakes:
(a) To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement to include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement.
(b) That, for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
(c) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.
The undersigned registrant hereby undertakes that, for purposes of determining any liability under the Securities Act of 1933, each filing of the registrant's annual report pursuant to section 13(a) or section 15(d) of the Securities Exchange Act of 1934 (and, where applicable, each filing of an employee benefit plan's annual report pursuant to section 15(d) of the Securities Exchange Act of 1934) that is incorporated by reference in the registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Act and will be governed by the final adjudication of such issue.
Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of New York, New York on August 26, 2003.
HUBEI PHARMACEUTICAL GROUP LTD.
(Registrant)
By: /s/ Reid Li
Reid Li,
President
Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the date indicated.
By: /s/ Reid Li
Reid Li,
President
Exhibit 5.1
DIETERICH & ASSOCIATES LETTERHEAD
August 26, 2003
Securities and Exchange Commission
450 Fifth Street, N.W.
Judiciary Plaza
Washington, DC 20549
Re: Hubei Pharmaceutical Group Ltd.
Ladies and Gentlemen:
This office represents Hubei Pharmaceutical Group Ltd., a Nevada corporation (the "Registrant") in connection with the Registrant's Registration Statement on Form S-8 under the Securities Act of 1933 (the "Registration Statement"), which relates to the sale of 2,000,000 shares of the Registrant's Common Stock issued to certain individuals for employment and consulting services (the "Shares").
In connection with our representation, we have examined such documents and undertaken such further inquiry as we consider necessary for rendering the opinion hereinafter set forth.
Based upon the foregoing, it is our opinion that the Registered Securities, when sold as set forth in the Registration Statement, will be legally issued, fully paid and non-assessable.
We hereby consent to the inclusion of this opinion in the Registration Statement and to the filing of this opinion as Exhibit 5.1 to the Registration Statement and with such state regulatory agencies in such states as may require such filing in connection with the registration of the Registered Securities for offer and sale in such states.
Very truly yours,
/s/ Christopher Dieterich
Dieterich & Associates
Exhibit 23.1
Included within Exhibit 5.1 (Opinion of Counsel)
Exhibit 23.2
INDEPENDENT AUDITOR'S CONSENT
We consent to the incorporation by reference in the Registration Statement of Hubei Pharmaceutical Group Ltd. on Form S-8 relating tot he registration of 2,000,000 common share issued to Ding Hong, Wei Jian Ping, Erwin Heuchert and Xiang Qian pursuant to certain services agreements, of our Auditors' Report, dated April 29, 2003, on the balance sheets of Hubei Pharmaceutical Group Ltd. as at January 31, 2003 and 2002, and the related statements of loss and deficit accumulated during the development stage, cash flows, and stockholders' equity for the years ended January 31, 2003 and 2002, and for the period from inception, December 18, 1998 to January 31, 2003.
Vancouver, Canada /s/ Morgan & Company
Chartered Accountants
August 26, 2003
/s/ Morgan & Company
Chartered Accountants
Vancouver, Canada
August 26 2003